Historical Valuation
Editas Medicine Inc (EDIT) is now in the Fair zone, suggesting that its current forward PS ratio of 11.01 is considered Fairly compared with the five-year average of -5.16. The fair price of Editas Medicine Inc (EDIT) is between 2.00 to 3.27 according to relative valuation methord.
Relative Value
Fair Zone
2.00-3.27
Current Price：2.07
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Editas Medicine Inc (EDIT) has a current Price-to-Book (P/B) ratio of 14.21. Compared to its 3-year average P/B ratio of 4.09 , the current P/B ratio is approximately 247.25% higher. Relative to its 5-year average P/B ratio of 3.96, the current P/B ratio is about 258.62% higher. Editas Medicine Inc (EDIT) has a Forward Free Cash Flow (FCF) yield of approximately -90.30%. Compared to its 3-year average FCF yield of -66.23%, the current FCF yield is approximately 36.34% lower. Relative to its 5-year average FCF yield of -44.59% , the current FCF yield is about 102.50% lower.
P/B
Median3y
4.09
Median5y
3.96
FCF Yield
Median3y
-66.23
Median5y
-44.59
Competitors Valuation Multiple
AI Analysis for EDIT
The average P/S ratio for EDIT competitors is 22.19, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT.O) exhibits a P/S ratio of 11.01, which is -50.36% above the industry average. Given its robust revenue growth of 12265.57%, this premium appears sustainable.
Performance Decomposition
AI Analysis for EDIT
1Y
3Y
5Y
Market capitalization of EDIT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of EDIT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is EDIT currently overvalued or undervalued?
Editas Medicine Inc (EDIT) is now in the Fair zone, suggesting that its current forward PS ratio of 11.01 is considered Fairly compared with the five-year average of -5.16. The fair price of Editas Medicine Inc (EDIT) is between 2.00 to 3.27 according to relative valuation methord.
What is Editas Medicine Inc (EDIT) fair value?
EDIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Editas Medicine Inc (EDIT) is between 2.00 to 3.27 according to relative valuation methord.
How does EDIT's valuation metrics compare to the industry average?
The average P/S ratio for EDIT's competitors is 22.19, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT) exhibits a P/S ratio of 11.01, which is -50.36% above the industry average. Given its robust revenue growth of 12265.57%, this premium appears sustainable.
What is the current P/B ratio for Editas Medicine Inc (EDIT) as of Jan 10 2026?
As of Jan 10 2026, Editas Medicine Inc (EDIT) has a P/B ratio of 14.21. This indicates that the market values EDIT at 14.21 times its book value.
What is the current FCF Yield for Editas Medicine Inc (EDIT) as of Jan 10 2026?
As of Jan 10 2026, Editas Medicine Inc (EDIT) has a FCF Yield of -90.30%. This means that for every dollar of Editas Medicine Inc’s market capitalization, the company generates -90.30 cents in free cash flow.
What is the current Forward P/E ratio for Editas Medicine Inc (EDIT) as of Jan 10 2026?
As of Jan 10 2026, Editas Medicine Inc (EDIT) has a Forward P/E ratio of -1.78. This means the market is willing to pay $-1.78 for every dollar of Editas Medicine Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Editas Medicine Inc (EDIT) as of Jan 10 2026?
As of Jan 10 2026, Editas Medicine Inc (EDIT) has a Forward P/S ratio of 11.01. This means the market is valuing EDIT at $11.01 for every dollar of expected revenue over the next 12 months.